Veru Inc.
VERU
We are a late clinical stage biopharmaceutical company focused on developing novel medicines for the treatment of cardiometabolic and inflammatory diseases. Our drug development program consists of two late-stage new chemical entities, enobosarm and sabizabulin.
Valuation & Multiples
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue
N/A
Net Income (TTM)
-$14M
▲ +39.9% YoY
Op. Margin
–
ROIC
-46.56%
▲ +26.5pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$26M
▼ -37.6% YoY
Op. Cash Flow (TTM)
-$26M
▼ -38.6% YoY
Net Debt
-$21M
Net Cash Position
Cash & Equiv.
$24M
5Y CAGR: -11.9%
Continue Research
Peers
Pharmaceutical Preparations · Pick stocks to compare with VERU
Veru (VERU) in three numbers
Questions about Veru
Is Veru a high-quality business?
Veru scores 10 out of 100 on Intrinsiqq's quality score, which makes it a lower-quality business on these measures. The score blends 6 checks computed from SEC filings. Its best check is net debt at -$21M, and its weakest is return on capital at -46.6%. The Quality tab shows every check against its target.
Does Veru (VERU) pay a dividend?
No. Veru (VERU) does not currently pay a dividend. The last payment in our data was in 2015, and nothing has been paid since. Nor has its share count fallen meaningfully over the last twelve months, so cash is kept in the business. The Dividends tab shows its cash returns.
Source: 10-Q filed 6 Aug 2026 (period ending 30 Jun 2026), SEC. Price: last close 20 Nov 2026. How this is calculated. Sector medians are approximate S&P 500 benchmarks and update periodically. Analysis, not investment advice.
Spot a number that looks wrong? Check it in VERU's SEC filings or
Download this analysis as a PDF (Pro)
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Keep analysing VERU
A free account gives you 10 stocks a day, a watchlist and price alerts.
Already have an account?
Or come back tomorrow. Stocks on your watchlist are always free to view.